ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 840

Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?

Alexandra Friedman1, Nicholas Young2, Paul Jensen3, Xiaolin Zhang4, Wael N. Jarjour5, Brad H. Rovin4, Daniel Birmingham3, Lee Hebert3 and Stacy P. Ardoin6, 1Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 2Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, 3Medicine, Ohio State University Medical Center, Columbus, OH, 4Division of Nephrology, Ohio State University Medical Center, Columbus, OH, 5Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 6Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Renal

Session Type: Abstract Submissions (ACR)

Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity. Urinary hepcidin-25 levels have been shown to decrease 2 months prior to renal SLE flare and show promise as a biomarker of lupus nephritis flare.  This study assessed serum hepcidin-25 levels before, during and after renal and non-renal SLE flares.

Methods: As part of the Ohio SLE Study (OSS), serum and urine were obtained in SLE patients prospectively at every 2 month intervals.  We identified 34 renal flare cycles in 21 patients and 22 non renal flare cycles in 17 patients. We measured serum 25 hepcidin levels at baseline, at time of flare and at 2 and 4 month intervals prior to flare and after flare.  Renal and non-renal flares were defined and adjudicated by OSS protocol. Serum hepcidin-25 was measured in duplicate by enzyme immune assay kits (Bachem).  Descriptive statistics were performed. 

Results: Serum hepcidin-25 levels showed substantial inter-patient variability and were presented relative to normalized baseline levels.  As shown in Figure 1, serum hepcidin 25 levels decreased significantly 2 months prior to renal flares but did not decrease prior to non renal flares. 

Conclusion: Serum hepcidin-25 levels decrease 2 months prior to renal SLE flare but not prior to non-renal SLE flare. To our knowledge, this is the first study to show that serum hepcidin 25 levels may predict renal SLE flare.  These findings need to be confirmed in larger prospective cohorts but support previous evidence that hepcidin 25 may be a biomarker for renal SLE flares.


Disclosure:

A. Friedman,
None;

N. Young,
None;

P. Jensen,
None;

X. Zhang,
None;

W. N. Jarjour,
None;

B. H. Rovin,

Genentech and Biogen IDEC Inc.,

5,

Teva Pharmaceuticals,

2,

Lilly,

5;

D. Birmingham,
None;

L. Hebert,
None;

S. P. Ardoin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-serum-hepcidin-25-levels-predict-sle-renal-or-non-renal-flares/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology